Morgan Stanley Elevates Johnson & Johnson to Overweight, Lifts Price Target to $262
Morgan Stanley upgraded Johnson & Johnson from Equalweight to Overweight and raised its price target to $262 from $200, citing improved confidence in the company’s forward growth and the clearing of uncertainty tied to Biopharma MFN agreements. The bank now forecasts 2026-2030 revenue and EPS compound annual growth rates of roughly 5.5% and 12%, re…